CLDN4 and breast cancer: Conversely, Kolokytha et al. reported that CLDN4 overexpression correlated with shorter disease-free survival and overall survival at five years, specifically in TNBC patients, but only increased Ki-67 proliferation index and tumor stage in luminal BC patients (19).